Codexis (CDXS) Total Non-Current Liabilities (2010 - 2026)
Codexis (CDXS) posted quarterly Total Non-Current Liabilities of $84.8 million for Q1 2026, up 8.75% year-over-year from $78.0 million in Q1 2025, and down 11.61% quarter-over-quarter from $95.9 million in Q4 2025.
Codexis (CDXS) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Codexis' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $84.8 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 8.75% year-over-year to $84.8 million; the TTM figure through Mar 2026 stood at $84.8 million (up 8.75% YoY), while the FY2025 annual figure was $95.9 million, up 18.72% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $84.8 million, down from $95.9 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $104.2 million in Q4 2022, with the low at $48.7 million in Q4 2023.
- The 5-year median for Total Non-Current Liabilities is $79.8 million (2022), against an average of $78.4 million.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities tumbled 53.26% in 2023, then soared 65.9% in 2024.
- Codexis' Total Non-Current Liabilities stood at $104.2 million in 2022, then sank by 53.26% to $48.7 million in 2023, then jumped by 65.9% to $80.8 million in 2024, then increased by 18.72% to $95.9 million in 2025, then fell by 11.61% to $84.8 million in 2026.
- Business Quant data shows CDXS's Total Non-Current Liabilities at $84.8 million in Q1 2026, $95.9 million in Q4 2025, and $84.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 9.32 Bn |
| 10 | Codexis | 145.23 Mn | 90.31 Mn | 11.40 Mn | 85.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 85.75 Mn |
| Mar 31, 2026 | 84.80 Mn |
| Dec 31, 2025 | 95.94 Mn |
| Sep 30, 2025 | 84.11 Mn |
| Jun 30, 2025 | 81.32 Mn |
| Mar 31, 2025 | 77.98 Mn |
| Dec 31, 2024 | 80.82 Mn |
| Sep 30, 2024 | 73.50 Mn |
| Jun 30, 2024 | 69.30 Mn |
| Mar 31, 2024 | 69.04 Mn |
| Dec 31, 2023 | 48.71 Mn |
| Sep 30, 2023 | 61.73 Mn |
| Jun 30, 2023 | 81.23 Mn |
| Mar 31, 2023 | 90.66 Mn |
| Dec 31, 2022 | 104.23 Mn |
| Sep 30, 2022 | 79.80 Mn |
| Jun 30, 2022 | 74.17 Mn |
| Mar 31, 2022 | 75.31 Mn |
| Dec 31, 2021 | 80.68 Mn |
| Sep 30, 2021 | 57.45 Mn |